CRADA Data. Collaborator and ICD will use reasonable efforts to keep CRADA Data confidential until published or until corresponding Patent Applications are filed. To the extent permitted by law, each Party will have the right to use any and all CRADA Data in and for any regulatory filing by or on behalf of the Party.
CRADA Data. Collaborator and ICD will use reasonable efforts to keep descriptions of CRADA Materials confidential until published or until corresponding Patent Applications are filed. Collaborator acknowledges that the basic research mission of PHS includes sharing with third parties for further research those research resources made in whole or in part with NIH funding. Consistent with this mission and the tenets articulated in “Sharing of Biomedical Research Resources: Principles and Guidelines for Recipients of NIH Research Grants and Contracts,” December 1999, available at xxxx://xxx.xxx.xxx.gov/policy/research_tool.aspx, following publication either Party may make available to third parties for further research those CRADA Materials made jointly by both PHS and Collaborator. Notwithstanding the above, if those joint CRADA Materials are the subject of a pending Patent Application or a Patent, or were created using a patent-pending or patented material or technology, the Parties may agree to restrict distribution or freely distribute them. Collaborator appreciates the need of ICD to advance its basic cancer research mission, and therefore will permit ICD to distribute jointly developed CRADA Materials, irrespective of patent protection, to academic institutions under material transfer agreements subject to review of the proposed research by Collaborator. Either Party may distribute those CRADA Materials made solely by the other Party only upon written consent from that other Party or that other Party’s designee.
CRADA Data. Collaborator and ICD will use reasonable efforts to keep CRADA Data and Raw Data confidential until published or until corresponding Patent Applications are filed. To the extent permitted by law, either Party will ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(2), (4), (5) and (6) and 230.406 have the right to use any and all CRADA Data and Raw Data in and for any regulatory filing by or on behalf of the Xxxxx. provided. however. That Collaborator shall have the exclusive right to use CRADA Data and Raw Data in regulatory filings for approvals and other commercial purposes for PSA-Tricom (Prostvac®).
CRADA Data. Collaborator and NCI will use reasonable efforts to keep CRADA Data confidential until published. To the extent permitted by law, each Party will have the right to use any and all CRADA Data in and for any regulatory filing by or on behalf of the Party. However, any unpublished CRADA Data provided by NCI or directly by NCI Investigators to Collaborator will be treated by Collaborator as Confidential Information until published.
